Activated Leukocyte Cell-Adhesion Molecule (ALCAM) Promotes Malignant Phenotypes of Malignant Mesothelioma
Authors:
- Hideki MurakamiHMHideki Murakami
- Tetsuya MizunoTMTetsuya Mizuno
- Makiko FujiiMFMakiko Fujii
- Yutaka KondoYKYutaka Kondo
- Noriyasu UsamiNUNoriyasu Usami
- Kohei YokoiKYKohei Yokoi
- Hirotaka OsadaHOHirotaka Osada
- Yoshitaka SekidoYSYoshitaka Sekido
- 1 May 2012
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 7 (5) , 890-899
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2009
- Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2009
- Trimodality Therapy With Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Adjuvant High-Dose Hemithoracic Radiation for Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2009
- Distinct mechanisms of tumor invasion and metastasisTrends in Molecular Medicine, 2007
- Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesotheliomaAnnals of Oncology, 2007
- Cellular and molecular parameters of mesotheliomaJournal of Cellular Biochemistry, 2006
- The pathogenesis of mesotheliomaSeminars in Diagnostic Pathology, 2006
- Advances in Malignant MesotheliomaNew England Journal of Medicine, 2005
- Malignant pleural mesotheliomaCurrent Problems in Cancer, 2004
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003